Calling all Australian investors! Argent BioPharma is spearheading novel epilepsy treatments with its innovative pharmaceuticals, and they’re inviting you to join them in their success! Learn more at https://argentbiopharma.com/
Argent Biopharma City: London Address: 21 Eccleston Place Website: https://argentbiopharma.com/
ASX-Listed Biopharmaceutical Company Has
Plans To Expand To Europe & US
Refractory epilepsy, also known as drug-resistant
epilepsy (DRE), affects 30% of generalised seizure
epilepsy patients, an equivalent of 15 million individuals
around the world.
These patients do not respond to
conventional medications,
underscoring the need for an
alternative biopharmaceutical
approach and leading Argent
BioPharma to develop CannEpil.
Following successful trials, CannEpil has been accepted by the Irish Health Product
Regulatory Authority and is currently in use by epilepsy patients in the UK and Ireland.
The product is already generating revenue under
early access schemes in both countries, with
treatment estimates per patient per annum
currently valued at £7000.
Argent BioPharma's other revenue-generating assets
include CimetrA, an anti-inflammatory drug for acute
lung injury and acute respiratory distress syndrome.
The company has plans to expand to larger markets in Europe and North America and will be filing an
IND application with the U.S. FDA for a 2030 launch.
https://argentbiopharma.com/
Find Out More At https://argentbiopharma.com/
Plans To Expand To Europe & US
Refractory epilepsy, also known as drug-resistant
epilepsy (DRE), affects 30% of generalised seizure
epilepsy patients, an equivalent of 15 million individuals
around the world.
These patients do not respond to
conventional medications,
underscoring the need for an
alternative biopharmaceutical
approach and leading Argent
BioPharma to develop CannEpil.
Following successful trials, CannEpil has been accepted by the Irish Health Product
Regulatory Authority and is currently in use by epilepsy patients in the UK and Ireland.
The product is already generating revenue under
early access schemes in both countries, with
treatment estimates per patient per annum
currently valued at £7000.
Argent BioPharma's other revenue-generating assets
include CimetrA, an anti-inflammatory drug for acute
lung injury and acute respiratory distress syndrome.
The company has plans to expand to larger markets in Europe and North America and will be filing an
IND application with the U.S. FDA for a 2030 launch.
https://argentbiopharma.com/
Find Out More At https://argentbiopharma.com/